CDKN2A and cancer: The primary rationale for genetic testing between the ages of 18 and 35 was to ensure that at-risk carriers would be old enough to make informed decisions about their hereditary cancer predisposition and its implications, including the potential financial consequences and reproductive decisions upon confirmation of the CDKN2A PV.